{"id":1202,"date":"2024-10-25T00:01:16","date_gmt":"2024-10-24T22:01:16","guid":{"rendered":"https:\/\/event.eortc.org\/ena2024\/?p=1202"},"modified":"2024-11-13T09:26:33","modified_gmt":"2024-11-13T08:26:33","slug":"key-genetic-mutations","status":"publish","type":"post","link":"https:\/\/event.eortc.org\/ena2024\/2024\/10\/25\/key-genetic-mutations\/","title":{"rendered":"Researchers find key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors"},"content":{"rendered":"

Friday 25 October 2024, Barcelona, Spain: <\/strong>Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs. The yet-to-be-published findings are presented on Friday at the 36th EORTC-NCI-AACR [1]<\/sup> Symposium on Molecular Targets and Cancer Therapeutics in Barcelona, Spain.<\/p>\n

Werner helicase (WRN) inhibitors are already being evaluated in phase I clinical trials in patients with tumours that have microsatellite instability (MSI) \u2013 a condition in which the genes responsible for monitoring and repairing mistakes in DNA replication stop functioning, and errors are introduced. This is also called mismatch repair deficiency. MSI occurs in several cancers, including 20% of bowel and stomach cancers.<\/p>\n

In 2019, a team at the Wellcome Sanger Institute, Cambridge, UK, led by Dr Mathew Garnett and including Dr Gabriele Picco as one of the first authors of the study, identified a protein in cancer cells, WRN, as being a vulnerability in MSI cancers. Since then, the team have shown that cancers resistant to standard-of-care therapies, including immunotherapy, rely heavily on WRN for survival.<\/p>\n

Dr Gabriele Picco, senior staff scientist and project lead in Dr Garnett\u2019s lab, told the Symposium: \u201cWRN inhibitors function through a mechanism called synthetic lethality, where two non-lethal genetic events cause cell death when combined. MSI cancer cells, which have a defect in DNA repair, become dependent on WRN for survival. When WRN is inhibited, these cells cannot repair DNA damage, leading to their death, while healthy cells remain unaffected.\u201d<\/p>\n

The team identified the first WRN inhibitor effective against cancer cells in laboratory tests earlier this year, and shortly after, two additional inhibitors were reported, which are now in clinical trials for MSI cancers, including colorectal (bowel) cancer. However, MSI cancers can develop resistance to WRN inhibitors.<\/p>\n

Dr Picco said: \u201cUsing advanced genetic screening and drug testing, our new study explores how colorectal cancer cells adapt to WRN inhibition and develop resistance, which is key for designing more effective therapies. After prolonged exposure to WRN inhibitors, we found that some cells acquired mutations in the WRN gene, the target of the drugs, rendering the drugs unable to bind and act on WRN effectively, allowing the cancer cells to survive.<\/p>\n

\u201cThese mutations in the WRN gene highlight a novel resistance mechanism and provide a way for us to test the efficacy of alternative WRN inhibitors that might be able to overcome this resistance.\u201d<\/p>\n

Speaking before the Symposium, Dr Garnett said: \u201cOur findings suggest that strategies that combine different drugs may be required to overcome resistance, including chemotherapy or immunotherapy. Moreover, approaches based on switching to alternative WRN inhibitors, including next-generation WRN inhibitors, might be also considered when resistance occurs. These results warrant further validation to advance clinical applications but have potential to inform clinical strategies and guide future treatment options.\u201d<\/p>\n

The findings might also enable clinicians to check how patients\u2019 cancers are responding to a particular WRN inhibitor by means of liquid biopsies. These analyse patient blood samples to detect any cancer cells and DNA circulating in the blood stream.<\/p>\n

\u201cTracking resistance mutations via liquid biopsy could be a potential strategy for monitoring treatment response,\u201d said Dr Picco.<\/p>\n

The team are now carrying out drug cross-resistance studies, which investigate whether MSI cancers that are resistant to one type of WRN inhibitor might also be resistant to others.<\/p>\n

\u201cWe are exploring combination strategies and identifying alternative drug targets to address resistance,\u201d he concluded.<\/p>\n

Dr Tim Greten, senior investigator at the Center for Cancer Research, National Cancer Institute, USA, is co-chair of the EORTC-NCI-AACR Symposium and was not involved in the research. He commented: \u201cThe work that this group is carrying out into the mechanisms of WRN inhibitor resistance is an important step forward in this field. Although WRN inhibitors are a new class of anti-cancer drug, we are already seeing that cancer cells are able to develop resistance to them, enabling tumours to start growing again. Working out ways to prevent this from happening will be important in MSI cancers, which include some colorectal, stomach, endometrial and ovarian cancers.\u201d<\/p>\n

(ends)<\/p>\n

Abstract no: 12<\/strong>, \u201cOn-target mutations drive resistance to WRN helicase inhibitors in microsatellite unstable colorectal cancer\u201d, by Gabriele Picco, presented in plenary session 7, Late Breaking Abstracts and Proffered Papers: Novel discoveries in drug development. Friday 25 October, 15:00-18:30 hrs CEST, Rooms 111+112.<\/p>\n

[1] EORTC [European Organisation for Research and Treatment of Cancer, NCI [National Cancer Institute], AACR [American Association for Cancer Research]. The Symposium takes place in Barcelona from 23-25 October 2024.<\/sup><\/p>\n

The research was funded by Wellcome Trust and GSK.<\/sup><\/p>\n

The European Organisation for Research and Treatment of Cancer (EORTC), the USA\u2019s National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) will join forces on 23-25 October 2024 to provide a platform for presenting recent advances in pre-clinical and clinical research. Around 1,300 international experts in the field will be discussing innovations in drug development, ground-breaking new data, the selection of new targets for anti-cancer drugs, and the impact of new discoveries in molecular biology, in order to improve the survival and quality of life of cancer patients.<\/sup><\/p>\n<\/div><\/div><\/div>

Recent posts<\/h4><\/div>
glyn<\/a><\/span><\/span>2024-11-13T09:26:15+01:00<\/span>

Scientists create cancer patients\u2019 \u2018digital twins\u2019 to predict how well treatments may work<\/a><\/h4>

Friday 25 October 2024, Barcelona, Spain: Researchers have shown that they can accurately re-create clinical trials of new treatments using \u2018digital twins\u2019 of real cancer patients. The technology, called FarrSight\u00ae-Twin, which is based on algorithms [...]<\/p><\/div><\/article>

glyn<\/a><\/span><\/span>2024-11-13T09:26:26+01:00<\/span>

Patients with advanced bladder cancer with alterations in the FGFR3 gene respond well to investigational drug, TYRA-300<\/a><\/h4>

Friday 25 October 2024, Barcelona, Spain: Patients with advanced bladder cancer that had spread to other parts of the body (metastasised) have responded well in a phase I clinical trial of an investigational drug, [...]<\/p><\/div><\/article>

glyn<\/a><\/span><\/span>2024-11-13T09:26:33+01:00<\/span>

Researchers find key genetic mutations in bowel cancer cells that lead to resistance to WRN inhibitors<\/a><\/h4>

Friday 25 October 2024, Barcelona, Spain: Researchers have discovered key mutations in certain cancer cells that make them resistant to WRN inhibitors, a new class of anti-cancer drugs. The yet-to-be-published findings are presented on Friday [...]<\/p><\/div><\/article>

glyn<\/a><\/span><\/span>2024-11-13T09:26:40+01:00<\/span>

New \u2018mini-protein\u2019 carries radiation dose directly to tumours without harming healthy tissues<\/a><\/h4>

Friday 25 October 2024, Barcelona, Spain: Researchers have shown for the first time that it is possible for a specially-designed \u2018mini-protein\u2019 to deliver a radiation dose directly to tumour cells expressing a protein on [...]<\/p><\/div><\/article>

glyn<\/a><\/span><\/span>2024-11-13T09:26:48+01:00<\/span>

Treatments used for HER2-positive breast cancers could help patients with rare gastrointestinal cancer<\/a><\/h4>

Trial of tucatinib and trastuzumab also showed benefits for HER2-mutated breast cancer: Thursday 24 October 2024, Barcelona, Spain: Drugs designed to target HER2-postive breast cancer could also benefit some patients with bile duct cancer, [...]<\/p><\/div><\/article>

frince<\/a><\/span><\/span>2024-11-13T09:26:57+01:00<\/span>

New drug, WNTinib, delays tumour growth and improves survival in mouse models of children\u2019s liver cancer<\/a><\/h4>

Wednesday 23 October 2024, Barcelona, Spain:\u00a0A new drug called WNTinib can delay the growth of tumours and improve survival in hepatoblastoma, a type of liver cancer that occurs in young children. This effect was [...]<\/p><\/div><\/article><\/section><\/div>

Share This Story<\/h4>
<\/i><\/a><\/span><\/i><\/a><\/span><\/i><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1202","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/posts\/1202","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/comments?post=1202"}],"version-history":[{"count":0,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/posts\/1202\/revisions"}],"wp:attachment":[{"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/media?parent=1202"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/categories?post=1202"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/event.eortc.org\/ena2024\/wp-json\/wp\/v2\/tags?post=1202"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}